Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

By Soeda Hiroshi   Shimodaira Hideki   Watanabe Mika   Suzuki Takao   Gamoh Makio   Mori Takahiro   Komine Keigo   Iwama Noriyuki   Kato Shunsuke   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 670-677

Springer Publishing Company

Access to resources Recommend Favorite

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer

By Paule Bernard  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1066-1072

Humana Press, Inc

Access to resources Recommend Favorite

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

By Tural Deniz   Batur Sebnem   Erdamar Sibel   Akar Emre   Kepil Nuray   Mandel Nil   Serdengeçti Süheyla  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1041-1049

Springer Publishing Company

Access to resources Recommend Favorite

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

By Qvortrup Camilla   Jensen Benny Vittrup   Jorgensen Trine Lembrecht   Nielsen Dorte   Bjerregaard Jon Kroll   Pfeiffer Per  

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 833-836

Informa Healthcare

Access to resources Recommend Favorite

Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer

By Benavides M.   García-Alfonso P.   Cobo M.   Muñoz-Martín A.   Gil-Calle S.   Carabantes F.   Villar E.   Graupera J.   Balcells M.   Pérez-Manga G.  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 255-262

Humana Press, Inc

Access to resources Recommend Favorite